ASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer

 Volver  Ver
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
 POSTER   09/2020
 Download  Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Clinical Pipeline - Solid Tumor
BeiGene Clinical Pipeline - Solid Tumor
 Volver